XML 93 R47.htm IDEA: XBRL DOCUMENT
v3.25.1

Share-based payments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Share-Based Payment Arrangements [Abstract] |
Disclosure of reconciliation of other equity instruments |
| NUMBER OF BSAs OUTSTANDING | MAXIMUM NUMBER OF SHARES TO BE ISSUED | NUMBER OF BSAs EXERCISED | NUMBER OF BSAs LAPSED | NUMBER OF BSAs OUTSTANDING | MAXIMUM NUMBER OF SHARES TO BE ISSUED
|  |  | FOR THE YEAR ENDED |  |
| AS OF JANUARY 1, 2022 | DECEMBER 31, 2022 | AS OF DECEMBER 31, 2022
BSAs granted under the Equity line agreement .................................... | 300,000 | 300,000 | — | (300,000) | — | —
The following tables summarize the data relating to BCEs as well as the assumptions used for the measurement thereof in accordance with IFRS 2 – Share-based Payment:
GRANT D ATE |  | TYPE |  | TOTAL NUMBER OF BCEs ISSUED |  | NUMBER OF BCE OUTSTAND ING AS OF JANUARY 1, 2024 |  | NUMBER OF ISSUED BCEs |  | NUMBER OF LAPSED BCEs |  | NUMBER OF EXERCISE D BCEs |  | NUMBER OF BCEs OUTSTAND ING |  | NUMBER OF BCEs EXERCISA BLE |  | MAXIMUM NUMBER OF SHARES TO BE ISSUED IF ALL CONDITIO NS ARE MET
|  |  |  | YEAR ENDED DECEMBER 31, 2024 |  | AS OF DECEMBER 31, 2024
2016-11-07 |  | BCE-2016-1 |  | 84,000 |  | 22,495 |  | — |  | (3,699) |  | — |  | 18,796 |  | 18,796 |  | 18,796
2017-01-23 |  | BCE-2017-1 |  | 67,374 |  | 67,000 |  | — |  | — |  | — |  | 67,000 |  | 41,735 |  | 67,000
2017-11-20 |  | BCE-2017-2 |  | 150,000 |  | 112,500 |  | — |  | — |  | — |  | 112,500 |  | 112,500 |  | 112,500
2017-11-20 |  | BCE-2017-4 |  | 67,374 |  | 67,373 |  | — |  | — |  | — |  | 67,373 |  | 33,686 |  | 67,373
2017-11-20 |  | BCE-2017-5 |  | 67,374 |  | 64,374 |  | — |  | (26,687) |  | (4,000) |  | 33,687 |  | 16,843 |  | 33,687
2018-03-15 |  | BCE-2018-1 |  | 22,000 |  | 11,980 |  | — |  | — |  | — |  | 11,980 |  | 11,980 |  | 11,980
2018-05-14 |  | BCE 2018-3 |  | 33,687 |  | 16,844 |  | — |  | (16,844) |  | — |  | — |  | — |  | —
2018-05-14 |  | BCE-2018-4 |  | 16,843 |  | 16,843 |  | — |  | — |  | — |  | 16,843 |  | 8,422 |  | 16,843
2018-05-14 |  | BCE-2018-5 |  | 22,000 |  | 6,000 |  | — |  | (4,000) |  | — |  | 2,000 |  | 2,000 |  | 2,000
|  | Total BCEs |  | 530,652 |  | 385,409 |  | — |  | (51,230) |  | (4,000) |  | 330,179 |  | 245,962 |  | 330,179
The following tables summarize the data relating to BSAs as well as the assumptions used for the measurement thereof in accordance with IFRS 2—Share-based Payment:
GRANT DATE |  | TYPE |  | TOTAL NUMBER OF BSAs ISSUED |  | NUMBER OF BCAs OUTSTAND ING AS OF JANUARY 1, 2024 |  | NUMBER OF ISSUED BSAs |  | NUMBER OF LAPSED BSAs |  | NUMBER OF EXERCISE D BSAs |  | NUMBER OF BSAs OUTSTAND ING |  | NUMBER OF BSAs EXERCISA BLE |  | MAXIMUM NUMBER OF SHARES TO BE ISSUED IF ALL CONDITIO NS ARE MET
|  |  |  | YEAR ENDED DECEMBER 31, 2024 |  | AS OF DECEMBER 31, 2024
2015-12-04 |  | BSA-2015-11 |  | 96,924 |  | 96,924 |  | — |  | — |  | — |  | 96,924 |  | 96,924 |  | 96,924
2015-12-04 |  | BSA-2015-12 |  | 82,000 |  | 16,400 |  | — |  | — |  | — |  | 16,400 |  | 16,400 |  | 16,400
2017-09-18 |  | BSA-2017-1 |  | 16,400 |  | 16,400 |  | — |  | — |  | — |  | 16,400 |  | 16,400 |  | 16,400
2018-01-22 |  | BSA-2018-1 |  | 49,200 |  | 16,400 |  | — |  | — |  | — |  | 16,400 |  | 16,400 |  | 16,400
2014-03-11 |  | BSA-2014-4 |  | 1,315 |  | 842 |  | — |  | (842) |  | — |  | — |  | — |  | —
2014-03-11 |  | BSA-2014-5 |  | 787 |  | 230 |  | — |  | (230) |  | — |  | — |  | — |  | —
2024-04-04 |  | BSA-2024-1 |  | 58,365 |  | — |  | — |  | — |  | — |  | 58,365 |  | — |  | 58,365
2024-04-04 |  | BSA-2024-2 |  | 19,455 |  | — |  | — |  | — |  | — |  | 19,455 |  | — |  | 19,455
|  | Total BSAs |  | 324,446 |  | 147,196 |  |  |  | (1,072) |  | — |  | 223,944 |  | 146,124 |  | 223,944
The following tables summarize the data relating to AGAs as well as the assumptions used for the measurement thereof in accordance with IFRS 2—Share-based Payment:
GRANT DATE |  | TYPE |  | TOTAL NUMBER OF AGAs ISSUED |  | NUMBER OF AGAs OUTSTANGIN G AS OF JANUARY 1, 2024 |  | NUMBER OF ISSUED AGAs |  | NUMBER OF LAPSED AGAs |  | NUMBER OF VESTED AGAs |  | NUMBER OF AGAs OUTSTANDIN G
|  |  |  |  | FOR THE YEAR ENDED DECEMBER 31, 2024 |  | AS OF DECEMBER 31, 2024
07/11/23 |  | AGA-2023-1 |  | 1,382,796 |  | 1,382,796 |  | — |  | (212,737) |  | (390,019) |  | 780,040
07/11/23 |  | AGA-2023-2 |  | 100,000 |  | 100,000 |  | — |  | — |  | (25,000) |  | 75,000
09/28/23 |  | AGA-2023-3 |  | 731,500 |  | 731,500 |  | — |  | (245,625) |  | — |  | 485,875
09/28/23 |  | AGA-2023-4 |  | 254,250 |  | 254,250 |  | — |  | (41,000) |  | — |  | 213,250
12/01/23 |  | AGA-2023-5 |  | 132,750 |  | 132,750 |  | — |  | (51,500) |  | — |  | 81,250
02/01/24 |  | AGA-2024-1 |  | 1,549,125 |  | — |  | 1,549,125 |  | (193,500) |  | — |  | 1,355,625
03/28/24 |  | AGA-2024-2 |  | 22,500 |  | — |  | 22,500 |  | — |  | — |  | 22,500
05/23/24 |  | AGA-2024-3 |  | 38,500 |  | — |  | 38,500 |  | — |  | — |  | 38,500
07/11/24 |  | AGA-2024-4 |  | 93,000 |  | — |  | 93,000 |  | — |  | — |  | 93,000
07/11/24 |  | AGA-2024-5 |  | 25,000 |  | — |  | 25,000 |  | — |  | — |  | 25,000
07/11/24 |  | AGA-2024-6 |  | 20,000 |  | — |  | 20,000 |  | — |  | — |  | 20,000
09/05/24 |  | AGA-2024-7 |  | 198,000 |  | — |  | 198,000 |  | — |  | — |  | 198,000
|  | Total AGAs |  | 4,547,421 |  | 2,601,296 |  | 1,946,125 |  | (744,362) |  | (415,019) |  | 3,388,040
Disclosure of main data and assumptions used for the measurement of other equity instruments | The fair value of the BSAs was determined at grant date using the Black Scholes model, with the following assumptions:
TYPE |  | FAIR VALUE OF THE UNDERLYING SHARE |  | FAIR VALUE OF THE BSA |  | NUMBER OF BSAs |  | SUBSCRIPTI ON PRICE |  | STRIKE PRICE PER SHARE |  | RISK FREE RATE |  | EXPECTED MATURITY |  | VOLATILITY
BSA 2024-1 |  | €14.06 |  | [€5.7-€6.5] |  | 58,365 |  | €2.57 |  | €13.10 |  | 4.30% |  | [5.4-6.9 years] |  | 60.41%
BSA 2024-2 |  | €14.06 |  | [€5.8-€6.6] |  | 19,455 |  | €2.57 |  | €13.10 |  | 4.30% |  | [5.5-7.0 years] |  | 60.41%
TYPE |  | FAIR VALUE OF THE UNDERLYING SHARE |  | FAIR VALUE OF THE AGA |  | AGA PRICE |  | MATURITY |  | VOLATILITY |  | RISK FREE RATE
AGA 2021 |  | €31.60 |  | €23.92 |  | €0.00 |  | 2022-07-31 |  | 49.0% |  | -1.00%
AGA 2023-1 (Tranches 1-4) |  | €15.98 |  | €15.98 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA 2023-1 (Tranche 5) |  | €15.98 |  | €3.62 |  | €0.00 |  | 2024-12-31 |  | 67.2% |  | 3.20%
AGA 2023-1 (Tranche 6) |  | €15.98 |  | €0.74 |  | €0.00 |  | 2024-07-11 |  | 67.2% |  | 3.20%
AGA 2023-2 (Tranche 1) |  | €15.98 |  | €15.98 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA 2023-2 (Tranche 2) |  | €15.98 |  | €9.59 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA 2023-3 |  | €14.92 |  | €14.92 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA 2023-4 |  | €14.92 |  | €14.92 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA 2023-5 |  | €9.16 |  | €9.16 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA 2024-1 |  | €12.26 |  | €12.26 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA 2024-2 |  | €13.40 |  | €13.40 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA-2024-3 |  | €12.76 |  | €12.76 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA-2024-4 |  | €12.54 |  | €12.54 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA-2024-5 |  | €12.54 |  | €12.54 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA-2024-6 |  | €12.54 |  | €12.54 |  | €0.00 |  | N/A |  | N/A |  | N/A
AGA-2024-7 |  | €10.80 |  | €10.80 |  | €0.00 |  | N/A |  | N/A |  | N/A
T he fair value of the Minimum Return Indemnifications was measured using the following assumptions:
Tranche B Minimum Return Indemnification (issued in March 2024) |  | AS OF MARCH 28, 2024 |  | AS OF DECEMBER 31, 2024
Final redemption scenario probability |  | 95% |  | 95%
Minimal return |  | 1.40 x |  | 1.40 x
Discount rate |  | 13% |  | 8%
Probability-weighted present value of shortfall payment (in thousands of €) |  | 1,959 (Final redemption) 68 (Tender offer) |  | 2,635 (Final redemption) 136 (Tender offer)
Probability-weighted fair value of tranche A-B warrants with MRI (in thousands of €) |  | 1,066 (Final redemption) |  | 104 (Final redemption)
Probability-weighted fair value of tranche A-B warrants without MRI (in thousands of €) |  | 1,410 (Final redemption) |  | 241 (Final redemption)
Total fair value of MRI (in thousands of €) |  | 1,615 (Final redemption, i.e. a+b-c) 68 (Tender offer) |  | 2,499 (Final redemption, i.e. a+b-c) 136 (Tender offer)
Fair value of Tranche B MRI (in thousands of €) |  | 1,683 |  | 2,636
Tranche C Minimum Return Indemnification (issued in June 2024) |  | AS OF JUNE 21, 2024 |  | AS OF DECEMBER 31, 2024
Final redemption scenario probability |  | 95% |  | 95%
Minimal return |  | 1.30 x |  | 1.30 x
Discount rate |  | 15% |  | 8%
(a) Probability-weighted present value of shortfall payment (in thousands of €) |  | 741 (Final redemption) 0 (Tender offer) |  | 1,160 (Final redemption) 43 (Tender offer)
(b) Probability-weighted fair value of tranche C warrants with MRI (in thousands of €) |  | 2,948 (Final redemption) |  | 684 (Final redemption)
(c) Probability-weighted fair value of tranche C warrants without MRI (in thousands of €) |  | 3,250 (Final redemption) |  | 903 (Final redemption)
Total fair value of MRI (in thousands of €) |  | 475 (Final redemption, i.e. a+b-c) 0 (Tender offer) |  | 941 (Final redemption, i.e. a+b-c) 43 (Tender offer)
Fair value of Tranche C MRI (in thousands of €) |  | 475 |  | 984
The main data and assumptions are the following:
Kreos/Claret Tranche A-B BSA - August 2023 |  | AS OF AUGUST 22, 2023 (Tranche A-B) |  | AS OF DECEMBER 31, 2023 |  | AS OF DECEMBER 31, 2024
Number of outstanding BSA |  | 214,198 |  | 214,198 |  | 214,198
Exercise price per share |  | €18.67 |  | €18.67 |  | €18.67
Ordinary share price |  | €17.10 |  | €9.82 |  | €6.76
Exercise date |  | 19/08/2030 (expiry) 18/02/2027 (tender offer) |  | 19/08/2030 (expiry) 18/02/2027 (tender offer) |  | 19/08/2030 (expiry) 18/02/2027 (tender offer)
7-year expiry scenario probability |  | 50% |  | 95% |  | 95%
Volatility |  | 71.9% (expiry) 65.2% (tender offer) |  | 59.5% (expiry) 64.9% (tender offer) |  | 44.3% (expiry) 44.3% (tender offer)
Dividend |  | —% |  | —% |  | —%
Risk-free rate |  | 3.00% |  | 2.30% |  | 2.9% (expiry) 2.9% (tender offer)
Fair value of issued Kreos/Claret Tranche A-B BSA |  | 2,092 |  | 920 |  | 243
Kreos/Claret Tranche C BSA - November 2023 |  | AS OF NOVEMBER 2, 2023 |  | AS OF DECEMBER 31, 2023 |  | AS OF DECEMBER 31, 2024
Number of outstanding BSA |  | 405,832 |  | 405,832 |  | 405,832
of which, number of conditional BSA |  | 202,915 |  | 202,916 |  | 0
Exercise price per share |  | €9.86 |  | €9.86 |  | €9.86
Ordinary share price |  | €8.89 |  | €9.82 |  | €6.67
Exercise date |  | 01/11/2030 (expiry) 18/02/2027 (tender offer) |  | 01/11/2030 (expiry) 18/02/2027 (tender offer) |  | 01/11/2030 (expiry) 18/02/2027 (tender offer)
7-year expiry scenario probability |  | 95% |  | 95% |  | 95%
Probability of Drawdown of Tranche C credit facility |  | 30% |  | 30% |  | Drawn on June 21, 2024
Volatility |  | 67.3% (expiry) 64.3% (tender offer) |  | 67.4% (expiry) 64.9% (tender offer) |  | 44.3% (expiry) 44.3% (tender offer)
Dividend |  | —% |  | —% |  | —%
Risk-free rate |  | 3.00% |  | 2.30% |  | 2.9% (expiry) 2.9% (tender offer)
Fair value of issued Kreos/Claret Tranche C BSA |  | 1,493 |  | 1,659 |  | 923
The Kreos A BSA and Kreos B BSA are measured at fair value using a Black-Scholes valuation model. The main data and assumptions are the following:
Kreos A BSA - June 1, 2018 |  | As of and for the year ended December 31, 2022 |  | As of May 24, 2023 (exercise date)
Number of outstanding Kreos A BSA |  | 110,957 |  | 110,957
Exercise price per share |  | €7.21 |  | €7.21
Ordinary share price |  | €6.18 |  | €18.57
Residual maturity |  | 5.6 years |  | 0.0 years
Volatility |  | 44.01% |  | N/A
Dividend |  | —% |  | N/A
Risk-free rate |  | 2.98% |  | N/A
Fair value of issued Kreos A BSA (in thousands of €) |  | 275 |  | 1,261
Kreos B BSA - June 1, 2019 |  | As of and for the year ended December 31, 2022 |  | As of May 24, 2023 (exercise date)
Number of outstanding Kreos B BSA |  | 74,766 |  | 74,766
Exercise price per share |  | €10.70 |  | €10.70
Ordinary share price |  | €6.18 |  | €18.57
Residual maturity |  | 6.4 years |  | 0.0 years
Volatility |  | 44.01% |  | N/A
Dividend |  | —% |  | N/A
Risk-free rate |  | 2.96% |  | N/A
Fair value of issued Kreos B BSA (in thousands of €) |  | 149 |  | 589
Disclosure of breakdown of the compensation expenses | Breakdown of the compensation expenses accounted for the period ended December 31, 2022, 2023 and 2024
TYPE (in thousands of euros) |  | YEAR ENDED DECEMBER 31, 2022 |  | YEAR ENDED DECEMBER 31, 2023 |  | YEAR ENDED DECEMBER 31, 2024
BCEs |  | (138) |  | (112) |  | (112)
BSAs |  | — |  | — |  | (211)
AGAs |  | (1,026) |  | (8,067) |  | (19,900)
Social taxes related to AGAs |  | (205) |  | (426) |  | (717)
Total |  | (1,369) |  | (8,605) |  | (20,941)

X
- Definition Share-Based Payment Arrangements [Abstract] + References No definition available. + Details
Name: | abvx_ShareBasedPaymentArrangementsAbstract
Namespace Prefix: | abvx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 47 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 50 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration